KONEXChemicals331660

Korea Miracle People Company

₩4,105▲ 1.36%2026-10-02 close

Market Cap

₩22.6B

Turnover

₩948,255

Volume

231 shares

Shares out.

5.5M

PER

—

PBR

—

EPS

—

Dividend Yield

0.00%

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

Profitability Restored; Biocide Approvals Are the Next Test

Having returned to full-year profitability in FY2024, the company's near-term trajectory hinges on securing U.S. and European biocide approvals for its mold-remover gel as the primary revenue expansion catalyst.

1
FY2024 standalone operating profit and net income both turned positive despite a 7.4% YoY revenue decline
2
Pursuing simultaneous domestic K-BPR approval and international biocide registrations (U.S. EPA, EU-BPR, UK GB-BPR), targeting completion in 2026–2027
3
Dual-segment structure: household goods (~67%, own brands TopStep/Silver Nano Step) + cosmetics OEM/ODM, with first-mover capability in domestic capsule-detergent manufacturing
4
Subsidiary of GPClub Co., Ltd. (55.8% shareholder); ultra-micro KONEX cap with near-zero daily trading liquidity — effectively single-share sessions
5
Structural tailwinds from the K-beauty export boom and rapid domestic pet-care market growth create OEM/ODM order expansion and animal quasi-drug product line opportunities

Business structure

Korea Miracle People (331660) was founded as a sole proprietorship in 2004, incorporated in May 2014, and listed on the KONEX exchange in October 2019; its headquarters, two production facilities (including a smart factory), and an R&D laboratory are all located in Pocheon, Gyeonggi Province.

The business operates across two segments — household goods (detergents) and cosmetics — with the former representing approximately 67% of total revenue as of FY2024.

In the household goods segment, the company produces laundry detergents, dish-washing detergents, and personal hygiene products under the proprietary 'TopStep' and 'Silver Nano Step' brands, distributed through TV home-shopping, online platforms, and large-format retail stores.

The cosmetics segment, initiated with JM Solution mask-pack OEM production in 2022, has since expanded to shampoo, conditioner, hair dye, and basic skincare, with a strategic focus on acquiring OEM/ODM contracts.

Approximately 50 product types across household, commercial, and industrial categories are exported to over 20 countries including the U.S., China, Russia, Japan, and Europe; however, domestic sales account for ~94% of revenue (FY2023), highlighting heavy home-market reliance.

As Korea's first developer of capsule-format laundry detergents (development initiated in 2019), the company installed capsule production machinery in 2020 and added two more units in 2023, building toward a specialized capsule-detergent OEM/ODM manufacturing platform.

Leveraging natural-extract-based eco-formulation expertise, the company is diversifying into pet-care products and animal quasi-drug categories to pursue higher-value-added product mix.

Its IP portfolio comprises 42 design rights, 28 trademarks, and 6 patents, with proprietary natural-extract concentration technology as the key competitive differentiator. The controlling shareholder is GPClub Co., Ltd.

(55.8%), a cosmetics and beauty goods wholesaler with 16 group affiliates, positioning Korea Miracle People as the core manufacturing subsidiary within the group.

Recent trends

In FY2024 (standalone basis), revenue declined 7.4% year-on-year, but both operating profit and net income turned positive — a meaningful profitability turnaround breaking from prior-year losses.

The revenue contraction is attributed to intensifying competition in home-shopping and offline retail channels alongside subdued consumer sentiment, while cost-structure improvements and operating efficiency gains drove the return to profitability.

FY2023 revenue composition shows product sales at 99.3%, merchandise at 0.7%, and other items at 0.1%, reflecting a purely manufacturing-oriented profile dominated by the household goods segment.

As of June 7, 2026, the closing price stood at KRW 3,845 (+1.18% day-on-day), but the session's total trading value was only KRW 3,845 — effectively a single-share transaction — confirming the near-zero liquidity characteristic of this KONEX micro-cap.

Based on available market data, the stock traded at approximately KRW 5,110 in October 2025 and the 52-week range extended from approximately KRW 4,970 to KRW 17,600, placing the current price significantly below recent levels.

At KRW 3,845 and an estimated share count of approximately 1.18 million shares (derived from the controlling shareholder's disclosed 660,000-share stake representing 55.8%), implied market capitalization is approximately KRW 4.5 billion — firmly in the ultra-micro-cap tier even within KONEX.

Per a June 1, 2026 Newspim report, the company's disclosure regarding K-BPR domestic approval proceedings and simultaneous international biocide registrations temporarily attracted investor attention to the stock.

As a KONEX-listed company, quarterly earnings reporting is not mandatory and institutional analyst coverage is minimal, making real-time operational monitoring challenging for external investors.

Outlook

The primary near-term catalyst is whether the company can obtain domestic K-BPR approval and simultaneous U.S.

EPA, EU-BPR, and UK GB-BPR biocide registrations for its 'Miracle Mold Remover Gel.' The company formalized its certification push through a partnership with the Korea Testing & Research Institute (KTR) in early 2026, targeting completion by end-2026 or H1 2027 at the latest.

Given that the global mold-remover market is projected to grow at a CAGR exceeding 7.2% to reach approximately USD 23.9 billion by 2032, successful certification would enable entry into a high-margin, regulatory-barrier-protected export segment.

In cosmetics OEM/ODM, the K-beauty export momentum — 2025 exports growing 10.7% year-on-year — provides a structural backdrop for incremental contract order growth, contingent on capacity and quality improvements at the company level.

The structural shift of the global laundry market toward capsule-format detergents is a favorable medium-term variable; as Korea's first domestic capsule-detergent developer with dedicated production equipment, the company is well positioned to benefit as an OEM/ODM supplier in this niche.

The domestic pet-care market, projected to grow at a CAGR of 9.6% to KRW 21.75 trillion by 2032, provides a meaningful long-term growth avenue for the company's animal quasi-drug lineup.

Revenue recovery timing remains uncertain, however, with certification delays, intensifying competition, and subdued consumer spending as persistent downside risks requiring close monitoring.

Bull factors

Confirmed Shift to Profitability

The FY2024 turnaround to positive operating and net income — despite a 7.4% revenue headwind — confirms that cost-structure improvements and operational efficiency gains have materially strengthened the company's earnings quality.

This profitability restoration signals enhanced cost-control capability, a positive structural shift for a business that had previously incurred recurring losses.

Given the small fixed-cost base typical of micro-cap manufacturers, any meaningful revenue recovery could translate into disproportionately rapid earnings expansion. Sustained profitability improvement post-turnaround would also progressively strengthen the balance sheet and fund incremental investment capacity.

Global Biocide Approvals as a High-Margin Export Engine

The global mold-remover market is projected to grow at a CAGR exceeding 7.2%, reaching approximately USD 23.9 billion by 2032 — a high-growth segment into which the company is pursuing regulation-driven entry. If U.S.

EPA, EU-BPR, and UK GB-BPR approvals are all secured, regulatory barriers would protect the company's export pricing from commodity-style competition, supporting a structurally higher-margin revenue profile.

With the KTR partnership formalized in early 2026, a successful certification outcome could serve as a dual catalyst for both earnings improvement and stock re-rating.

From a strategic perspective, this represents a concrete and executable export diversification initiative against a revenue base currently dominated (~94%) by the domestic market.

Compound Tailwinds from Capsule Detergent and K-Beauty OEM

The global laundry detergent market is restructuring around capsule-format products, and as Korea's first developer of capsule detergents since 2019, the company has proactively built dedicated production capacity in this growing niche.

K-beauty cosmetics exports grew 10.7% year-on-year in 2025, and this sustained sectoral momentum structurally expands OEM/ODM order opportunities for mid-tier contract manufacturers.

Backed by an in-house R&D center and natural-extract-based formulation technology, the company can differentiate on quality and technical capability relative to lower-cost OEM peers, potentially supporting better contract pricing.

The domestic pet-care market, projected to grow at a CAGR of 9.6% through 2032, offers the company's animal quasi-drug product line a meaningful medium-to-long-term incremental growth vector.

Bear factors

Revenue Decline and Heavy Domestic Dependency

Standalone revenue declined 7.4% year-on-year in FY2024, reflecting persistent growth stagnation rather than a one-time fluctuation. With domestic sales accounting for approximately 94% of revenue (FY2023), the company is highly vulnerable to domestic consumer sentiment deterioration.

Large-cap brands such as LG H&H and Aekyung Industrial dominate home-shopping and offline retail channels, posing a structural challenge to brand price protection and channel expansion for a smaller competitor.

Without visible progress in export diversification and OEM/ODM order momentum, a reversal of the revenue decline trajectory could remain delayed.

Absent KONEX Liquidity and Information Asymmetry

The daily trading value of KRW 3,845 (effectively one share) as of June 7, 2026 renders normal price discovery virtually inoperable.

The KONEX market imposes lighter quarterly disclosure obligations and attracts minimal institutional coverage relative to KOSPI/KOSDAQ, resulting in significant information asymmetry for investors.

The high susceptibility to price distortion from isolated transactions means that short-term share price movements are unlikely to accurately reflect intrinsic business value. This structural liquidity deficit represents a key practical constraint on the ability to establish or exit positions at fair prices.

Certification Delays and Regulatory Uncertainty

U.S. EPA, EU-BPR, and UK GB-BPR biocide registrations involve complex scientific data submissions and regulatory agency reviews that can readily extend beyond the anticipated one-year timeline.

The domestic K-BPR transition process could also encounter additional requirements during the Ministry of Environment review, further delaying completion.

Any delays or rejections would push back the company's entry into high-margin global export markets and prolong the timeline for the growth narrative to materialize in financial results.

As a smaller company with relatively limited regulatory compliance resources, the risk of execution shortfalls in navigating multi-jurisdictional approval processes is higher than for large-cap chemical peers.

Risk factors

Macro and Consumer Risk

Prolonged weakness in domestic consumer sentiment could further reduce sales in the household goods segment, which accounts for approximately 67% of total revenue, compounding the existing revenue decline trend.

Rising raw material costs — including surfactants and natural extracts — would directly pressure the cost structure and could erode the recently achieved profitability recovery.

In a global economic slowdown scenario, the company's low export exposure (~6% of revenue) limits its ability to offset domestic headwinds through geographic diversification, while exchange rate volatility could simultaneously impact both raw material import costs and export proceeds.

Regulatory and Certification Risk

Domestic K-BPR and international biocide registrations (EPA/EU-BPR/GB-BPR) require multi-stage scientific validations and regulatory authority reviews, carrying non-trivial risks of unexpected delays or adverse approval decisions.

In the cosmetics segment, evolving ingredient usage regulations and labeling requirements across export markets could affect OEM/ODM contract conditions and export market access.

The tightening trend in domestic household chemical product safety regulations may impose additional re-certification and re-testing burdens on the existing detergent product lineup, representing a potential increase in compliance costs.

Governance and Concentration Risk

With GPClub Co., Ltd. holding 55.8% of shares, management decisions may be unduly influenced by the controlling shareholder's interests, embedding a structural risk for minority shareholders with limited recourse.

The lighter disclosure regime of the KONEX market and near-total absence of institutional analyst coverage make it difficult for outside investors to monitor operational developments on a timely basis, amplifying information asymmetry.

Changes in GPClub's group-level financial condition or affiliate-level risks could potentially spill over to Korea Miracle People, given its status as a dependent manufacturing subsidiary, necessitating monitoring of the broader group's financial health.

Overall view

Korea Miracle People took a meaningful first step toward financial recovery by returning to operating and net profitability in FY2024, but persistent revenue decline and the near-total absence of trading liquidity in the KONEX market remain fundamental constraints on any holistic investment assessment.

The domestic and international biocide certification strategy for the mold-remover gel represents a credibly directional pathway for a small-cap detergent manufacturer to enter a high-margin, barrier-protected global export segment, though multi-year regulatory timelines and execution uncertainty limit its near-term investment appeal.

The medium-to-long-term growth narratives — first-mover capsule-detergent capability, K-beauty OEM order expansion, and the domestic pet-care boom — are directionally constructive but have yet to translate into concrete financial metrics that investors can objectively evaluate.

Given the KONEX market's thin disclosure regime, minimal institutional coverage, and structural price-discovery limitations, the current juncture calls for systematic operational monitoring rather than a definitive investment stance.

The pace of biocide certification progress and the visibility of a revenue inflection point will be the primary triggers for any future reassessment.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 7 more articles and sources

Report written 2026-06-08 · Data as of 2026-06-05

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.